Oddity Tech Ltd (ODD) Stock Analysis and Metrics

Oddity Tech

NASDAQ: ODD

$16.27 ▲ +0.93 (+6.06%)

At close: Jul 27, 2026 · 11:18 AM UTC

Financial Ratios

Market Cap60.96 Mn

P/E0.46

P/S0.00

Div. Yield0.00

Total Debt (Qtr)584.37 Mn

Revenue Growth (1y) (Qtr)123.52 Mn

Add ratio to table…

About

ODDITY Tech Ltd is a consumer technology company that transforms the global beauty and wellness market through its integrated online platform. The company leverages data science machine learning and computer vision to deliver personalized product experiences and develop science-backed formulations. It operates a direct-to-consumer business model that supports proprietary brands and in-house biotechnology innovation.

ODDITY Tech Ltd generates revenue primarily through the sale of its beauty and wellness products across its brand portfolio including IL MAKIAGE SpoiledChild and METHODIQ. The company sells directly to consumers via its digital platform which uses proprietary algorithms for product matching and customer engagement. Revenue is derived from online transactions where users purchase skincare haircare supplements color cosmetics and medical-grade telehealth services.

The company operates through the following segments: IL MAKIAGE SpoiledChild METHODIQ and New Ventures.

• IL MAKIAGE is a prestige digital beauty brand that uses ODDITY’s technology platform to deliver personalized online experiences in face complexion skin eyes brows and lips categories. It leverages data science machine learning and computer vision to match products to consumer needs and has converted millions of users from offline to online beauty shopping since its 2018 launch in the United States.

• SpoiledChild is a prestige online-only wellness brand offering skincare haircare and supplements with a focus on anti-aging sustainability and individualized care. It features patented refillable packaging to reduce waste and empowers consumers to control their aging process through data-driven product recommendations.

• METHODIQ is a medical telehealth platform launched in 2025 that delivers high-efficacy dermatology treatments at scale. It uses computer vision and AI for personalized skin assessments provides continuous care via a tracking app and offers proprietary products designed to maximize efficacy minimize side effects and deliver a premium beauty experience.

• New Ventures is an in-house brand incubator established in 2019 to develop additional digitally native brands for future launch. It targets high-demand low-satisfaction categories in beauty and wellness where legacy brands lack sufficient technology integration and aims to disrupt markets through innovation and proprietary product development.

ODDITY Tech Ltd holds a leading position in the online direct-to-consumer beauty and wellness industry and believes it is the world’s largest such company by revenue. Its competitive advantage stems from a technology-first approach that combines proprietary AI machine learning and computer vision capabilities with in-house biotechnology through ODDITY LABS. This enables rapid product innovation data-driven marketing and superior product performance differentiating it from traditional beauty companies reliant on offline distribution and legacy formulation methods.

ODDITY Tech Ltd serves individual consumers globally who seek personalized science-backed beauty and wellness solutions through online channels. Its customer base includes users of its IL MAKIAGE SpoiledChild and METHODIQ platforms spanning the United States United Kingdom continental Europe and Australia with international sales representing approximately 18% of net revenue for the year ended December 31 2025.

Investment Thesis

▲ Bull case

ODDITY's successful remediation of the Try Before You Buy model demonstrates structural resilience and adaptability in its core business model, shifting 40% of acquisition revenue from TBYB to standard Buy without impacting unit economics. This operational flexibility, achieved through extensive testing and infrastructure adjustments, indicates the company's ability to navigate complex platform dynamics while maintaining profitability per customer. The fact that this shift was accomplished despite the technical dislocation with its largest advertising partner underscores the strength of ODDITY's internal capabilities in diagnosing and resolving funnel inefficiencies. This experience positions the company to better withstand future algorithmic changes, as it has proven it can isolate variables, test solutions, and implement fixes without eroding the economic foundation of its customer acquisition strategy. Such adaptability is a competitive moat that many pure-play D2C beauty brands lack, especially those reliant on third-party platforms with limited control over user experience and data signaling. The preservation of unit economics during this transition suggests that ODDITY's underlying customer value proposition remains intact and scalable, providing a foundation for accelerated recovery once advertising efficiency normalizes. This capability to innovate within constraints while protecting core economics is a leading indicator of long-term operational excellence and should be valued as a strategic advantage beyond the current cyclical downturn.
ODDITY Labs' pipeline of novel molecules targeting high-prevalence dermatological conditions represents a significant, underappreciated value driver with potential to transform the company from a beauty brand operator into a science-led wellness innovator. The advancement of Neurexa (eczema treatment) and Zeralaq (acne scalp prevention) into the METHODIQ lineup, coupled with ongoing human-focused trials for anti-aging and hyperpigmentation molecules, signals progression beyond early-stage discovery into clinical validation phases. These initiatives address large, underserved markets — such as the 31.6 million Americans affected by eczema and nearly 50 million dealing with acne — where current treatments often involve systemic drugs with notable side effects. ODDITY's focus on topical, molecularly precise solutions with minimal adverse effects aligns with growing consumer demand for clean, efficacious, and dermatologist-recommended products. The integration of these lab-developed assets into METHODIQ not only enhances product differentiation but also creates a defensible IP moat that is difficult for competitors to replicate quickly. Given the regulatory de-risking potential from FDA movement on peptides like GHK-Cu and BPC 157 toward Category 1 status, ODDITY is positioned to accelerate formulation and market access for high-efficacy skincare innovations. This scientific engine could generate higher-margin, recurring revenue streams less dependent on volatile user acquisition costs, thereby diversifying revenue and improving long-term margin sustainability.
The company's strong repeat customer economics, evidenced by stable 12-month net revenue repeat rates and contribution margins, confirm that brand health and product efficacy remain intact despite the advertising-driven acquisition downturn. Repeat sales represented approximately two-thirds of Q1 net revenue, up from 56% in the prior year period, indicating increasing customer loyalty and retention — a direct result of the Try Before You Buy model reducing purchase risk and fostering trust. This cohort resilience suggests that once acquisition efficiency improves, the return on marketing spend will be amplified by high LTV:CAC ratios, enabling faster profitability recovery than implied by top-line trends alone. Furthermore, the decision to maintain acquisition spend during the downturn — despite poor efficiency — was strategic: it preserved algorithmic signal integrity to facilitate faster recalibration, avoiding a deeper spiral that could have resulted from complete spend withdrawal. This discipline reflects a sophisticated understanding of platform dynamics, where transient pain is accepted to preserve long-term growth potential. The combination of durable customer relationships, repeat-driven profitability, and intentional spend to accelerate recovery creates a powerful inflection point scenario where even modest CPA improvement could trigger disproportionate earnings upside due to operating leverage on a highly retentive base.

ODDITY's successful remediation of the Try Before You Buy model demonstrates structural resilience and adaptability in its core business model, shifting 40% of acquisition revenue from TBYB to standard Buy without impacting unit economics. This operational flexibility, achieved through extensive testing and infrastructure adjustments, indicates the company's ability to navigate complex platform dynamics while maintaining profitability per customer. The fact that this shift was accomplished despite the technical dislocation with its largest advertising partner underscores the strength of ODDITY's internal capabilities in diagnosing and resolving funnel inefficiencies. This experience positions the company to better withstand future algorithmic changes, as it has proven it can isolate variables, test solutions, and implement fixes without eroding the economic foundation of its customer acquisition strategy. Such adaptability is a competitive moat that many pure-play D2C beauty brands lack, especially those reliant on third-party platforms with limited control over user experience and data signaling. The preservation of unit economics during this transition suggests that ODDITY's underlying customer value proposition remains intact and scalable, providing a foundation for accelerated recovery once advertising efficiency normalizes. This capability to innovate within constraints while protecting core economics is a leading indicator of long-term operational excellence and should be valued as a strategic advantage beyond the current cyclical downturn.
ODDITY Labs' pipeline of novel molecules targeting high-prevalence dermatological conditions represents a significant, underappreciated value driver with potential to transform the company from a beauty brand operator into a science-led wellness innovator. The advancement of Neurexa (eczema treatment) and Zeralaq (acne scalp prevention) into the METHODIQ lineup, coupled with ongoing human-focused trials for anti-aging and hyperpigmentation molecules, signals progression beyond early-stage discovery into clinical validation phases. These initiatives address large, underserved markets — such as the 31.6 million Americans affected by eczema and nearly 50 million dealing with acne — where current treatments often involve systemic drugs with notable side effects. ODDITY's focus on topical, molecularly precise solutions with minimal adverse effects aligns with growing consumer demand for clean, efficacious, and dermatologist-recommended products. The integration of these lab-developed assets into METHODIQ not only enhances product differentiation but also creates a defensible IP moat that is difficult for competitors to replicate quickly. Given the regulatory de-risking potential from FDA movement on peptides like GHK-Cu and BPC 157 toward Category 1 status, ODDITY is positioned to accelerate formulation and market access for high-efficacy skincare innovations. This scientific engine could generate higher-margin, recurring revenue streams less dependent on volatile user acquisition costs, thereby diversifying revenue and improving long-term margin sustainability.
The company's strong repeat customer economics, evidenced by stable 12-month net revenue repeat rates and contribution margins, confirm that brand health and product efficacy remain intact despite the advertising-driven acquisition downturn. Repeat sales represented approximately two-thirds of Q1 net revenue, up from 56% in the prior year period, indicating increasing customer loyalty and retention — a direct result of the Try Before You Buy model reducing purchase risk and fostering trust. This cohort resilience suggests that once acquisition efficiency improves, the return on marketing spend will be amplified by high LTV:CAC ratios, enabling faster profitability recovery than implied by top-line trends alone. Furthermore, the decision to maintain acquisition spend during the downturn — despite poor efficiency — was strategic: it preserved algorithmic signal integrity to facilitate faster recalibration, avoiding a deeper spiral that could have resulted from complete spend withdrawal. This discipline reflects a sophisticated understanding of platform dynamics, where transient pain is accepted to preserve long-term growth potential. The combination of durable customer relationships, repeat-driven profitability, and intentional spend to accelerate recovery creates a powerful inflection point scenario where even modest CPA improvement could trigger disproportionate earnings upside due to operating leverage on a highly retentive base.

▼ Bear case

ODDITY's continued reliance on a single dominant advertising partner for the majority of its new user acquisition creates an unacceptably high concentration risk, especially given the partner's opaque algorithmic behavior and the company's limited ability to influence or predict changes. Despite advertising on other platforms, the CEO acknowledged that this partner commands 'way more than 50%' of the U.S. beauty ad market, making meaningful diversification economically unfeasible at scale. This dependency was starkly revealed when simultaneous CPA spikes occurred across IL MAKIAGE accounts in the U.S., Canada, U.K., Australia, and Israel — a pattern that strongly suggests a systemic platform-side issue rather than brand-specific fatigue or market saturation. The fact that the company cannot guarantee the May CPA improvement will persist, coupled with the CFO's admission that Q2 guidance assumes 'CPA remains similarly difficult,' indicates a lack of confidence in sustained recovery. This structural vulnerability is exacerbated by ODDITY's 100% D2C model, which lacks the omnichannel buffer that incumbent beauty brands use to mitigate platform volatility. Until the company can demonstrably reduce its reliance on this single partner — either through technological innovation, creative diversification, or negotiated safeguards — its growth trajectory remains hostage to external algorithmic whims, making forecasts inherently speculative and downside risks materially underpriced by the market.
The deterioration in gross margin, which compressed approximately 520 basis points year-over-year to 69.7% in Q1, signals deeper operational strain than management acknowledges, particularly given that the decline was driven by both product mix shifts and lower AOV — factors that may persist beyond the advertising dislocation. While management attributed part of the compression to temporary noise from remediation tests (e.g., altering TBYB return policies, turning off tech products), the sustained pressure on margins from operating deleverage and lower revenue volume suggests a more entrenched challenge. The shift toward higher-margin SpoiledChild relative to IL MAKIAGE did not offset the AOV decline, implying that even the company's faster-growing brand is unable to sustain pricing power or basket size under current conditions. Furthermore, the elevated inventory position exiting Q1 — due to revenue shortfall relative to prior purchase plans — raises the risk of future write-downs or promotional clearance if demand does not recover as anticipated. Gross margin is a leading indicator of pricing power, production efficiency, and product mix health; its persistent erosion, especially in a discretionary category like beauty, raises concerns about whether ODDITY can maintain its historical profitability profile even after CPA normalization, particularly if consumer sensitivity to price increases or economic headwinds constrain AOV recovery.
METHODIQ's projected $25 million in revenue for FY26, while presented as a strong start, represents an immaterial contribution to overall company scale and may divert focus and capital from core brands without delivering proportional strategic value. Despite enthusiasm about its 28-product line spanning prescriptions, nonprescription treatments, and medical-grade makeup, METHODIQ remains an early-stage venture with unproven monetization beyond initial adoption. The company's own caution — stating it does not want to 'accelerate it before you optimize the exact funnels and products' — acknowledges that meaningful scaling requires significant iteration, which conflicts with the need to allocate scarce resources toward resolving the IL MAKIAGE crisis. Meanwhile, the biotech talent environment in Boston has strengthened, increasing the risk of attrition in ODDITY Labs if competitors offer more competitive compensation or clearer paths to impact. The opportunity cost of sustaining METHODIQ's development — including clinical testing, regulatory navigation, and supply chain complexity — could be substantial, especially if the brand fails to achieve meaningful penetration in the crowded telehealth and dermatology markets. Given that METHODIQ's success is framed as being 'in line with SpoiledChild's strong success in year 1,' yet SpoiledChild itself is navigating higher (though less severe) CPA costs, there is little evidence that METHODIQ will escape the same acquisition headwinds affecting the rest of the portfolio. Without a clear path to profitability or defensible differentiation in a regulated medical space, METHODIQ risks becoming a persistent drag on resources rather than a growth catalyst, particularly if management continues to prioritize it over fixing the core revenue engine.

ODDITY's continued reliance on a single dominant advertising partner for the majority of its new user acquisition creates an unacceptably high concentration risk, especially given the partner's opaque algorithmic behavior and the company's limited ability to influence or predict changes. Despite advertising on other platforms, the CEO acknowledged that this partner commands 'way more than 50%' of the U.S. beauty ad market, making meaningful diversification economically unfeasible at scale. This dependency was starkly revealed when simultaneous CPA spikes occurred across IL MAKIAGE accounts in the U.S., Canada, U.K., Australia, and Israel — a pattern that strongly suggests a systemic platform-side issue rather than brand-specific fatigue or market saturation. The fact that the company cannot guarantee the May CPA improvement will persist, coupled with the CFO's admission that Q2 guidance assumes 'CPA remains similarly difficult,' indicates a lack of confidence in sustained recovery. This structural vulnerability is exacerbated by ODDITY's 100% D2C model, which lacks the omnichannel buffer that incumbent beauty brands use to mitigate platform volatility. Until the company can demonstrably reduce its reliance on this single partner — either through technological innovation, creative diversification, or negotiated safeguards — its growth trajectory remains hostage to external algorithmic whims, making forecasts inherently speculative and downside risks materially underpriced by the market.
The deterioration in gross margin, which compressed approximately 520 basis points year-over-year to 69.7% in Q1, signals deeper operational strain than management acknowledges, particularly given that the decline was driven by both product mix shifts and lower AOV — factors that may persist beyond the advertising dislocation. While management attributed part of the compression to temporary noise from remediation tests (e.g., altering TBYB return policies, turning off tech products), the sustained pressure on margins from operating deleverage and lower revenue volume suggests a more entrenched challenge. The shift toward higher-margin SpoiledChild relative to IL MAKIAGE did not offset the AOV decline, implying that even the company's faster-growing brand is unable to sustain pricing power or basket size under current conditions. Furthermore, the elevated inventory position exiting Q1 — due to revenue shortfall relative to prior purchase plans — raises the risk of future write-downs or promotional clearance if demand does not recover as anticipated. Gross margin is a leading indicator of pricing power, production efficiency, and product mix health; its persistent erosion, especially in a discretionary category like beauty, raises concerns about whether ODDITY can maintain its historical profitability profile even after CPA normalization, particularly if consumer sensitivity to price increases or economic headwinds constrain AOV recovery.
METHODIQ's projected $25 million in revenue for FY26, while presented as a strong start, represents an immaterial contribution to overall company scale and may divert focus and capital from core brands without delivering proportional strategic value. Despite enthusiasm about its 28-product line spanning prescriptions, nonprescription treatments, and medical-grade makeup, METHODIQ remains an early-stage venture with unproven monetization beyond initial adoption. The company's own caution — stating it does not want to 'accelerate it before you optimize the exact funnels and products' — acknowledges that meaningful scaling requires significant iteration, which conflicts with the need to allocate scarce resources toward resolving the IL MAKIAGE crisis. Meanwhile, the biotech talent environment in Boston has strengthened, increasing the risk of attrition in ODDITY Labs if competitors offer more competitive compensation or clearer paths to impact. The opportunity cost of sustaining METHODIQ's development — including clinical testing, regulatory navigation, and supply chain complexity — could be substantial, especially if the brand fails to achieve meaningful penetration in the crowded telehealth and dermatology markets. Given that METHODIQ's success is framed as being 'in line with SpoiledChild's strong success in year 1,' yet SpoiledChild itself is navigating higher (though less severe) CPA costs, there is little evidence that METHODIQ will escape the same acquisition headwinds affecting the rest of the portfolio. Without a clear path to profitability or defensible differentiation in a regulated medical space, METHODIQ risks becoming a persistent drag on resources rather than a growth catalyst, particularly if management continues to prioritize it over fixing the core revenue engine.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Household & Personal Products

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	PG	PROCTER & GAMBLE Co	347.71 Bn	20.84	4.01	37.03 Bn
2	UL	Unilever Plc	134.95 Bn	28.45	4.07	32.92 Bn
3	CL	Colgate Palmolive Co	73.90 Bn	33.36	3.55	7.94 Bn
4	KVUE	Kenvue Inc.	37.36 Bn	23.04	2.44	8.66 Bn
5	KMB	Kimberly Clark Corp	37.09 Bn	93.20	2.24	7.08 Bn
6	EL	Estee Lauder Companies Inc	29.61 Bn	-155.03	2.00	7.31 Bn
7	CHD	Church & Dwight Co Inc /De/	23.45 Bn	25.07	420.32	2.40 Bn
8	CLX	Clorox Co /De/	11.83 Bn	15.36	1.75	2.49 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password